结直肠癌肿瘤内皮细胞中 SOX17 的表达及其与患者良好预后的关系。

IF 2.9 4区医学 Q2 PATHOLOGY

Pathology, research and practice Pub Date : 2024-09-25 DOI:10.1016/j.prp.2024.155610

Hirokatsu Hayashi , Yuki Hanamatsu , Chiemi Saigo , Nobuhisa Matsuhashi , Tamotsu Takeuchi

{"title":"结直肠癌肿瘤内皮细胞中 SOX17 的表达及其与患者良好预后的关系。","authors":"Hirokatsu Hayashi , Yuki Hanamatsu , Chiemi Saigo , Nobuhisa Matsuhashi , Tamotsu Takeuchi","doi":"10.1016/j.prp.2024.155610","DOIUrl":null,"url":null,"abstract":"<div><div>The high mortality rate of colorectal cancer (CRC) highlights the need for new treatment strategies; however, the venous invasion mechanisms in tumor endothelial cells within CRC remain unexplored. Therefore, we investigated the clinicopathological features of SRY-box transcription factor 17 (SOX17) in CRC. Immunohistochemical staining was performed on 55 CRC tissue specimens using a SOX17-specific antibody, followed by Kaplan–Meier and Cox proportional hazards regression analyses. SOX17 immunoreactivity was detected in the endothelial cells of tumor-penetrating vessels in 35/55 CRC samples. Kaplan–Meier analysis indicated that patients with SOX17 immunoreactivity had favorable overall and progression-free survival (log-rank test, <em>P</em> = 0.03 and 0.02, respectively). Notably, tumor endothelial SOX17 immunoreactivity was associated with a favorable prognosis in patients with stage III or IV disease (OS, <em>P</em> = 0.0089; PFS, <em>P</em> = 0.0065). Cox proportional hazard regression analysis indicated that SOX17 immunoreactivity is an independent factor for predicting favorable overall and progression-free survival in CRC (<em>P</em> = 0.02 and 0.01, respectively). The present findings suggest that SOX17 expression in tumor endothelial cells is a potential indicator of favorable prognosis in patients with CRC.</div></div>","PeriodicalId":19916,"journal":{"name":"Pathology, research and practice","volume":null,"pages":null},"PeriodicalIF":2.9000,"publicationDate":"2024-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"SOX17 expression in tumor endothelial cells in colorectal cancer and its association with favorable outcomes in patients\",\"authors\":\"Hirokatsu Hayashi , Yuki Hanamatsu , Chiemi Saigo , Nobuhisa Matsuhashi , Tamotsu Takeuchi\",\"doi\":\"10.1016/j.prp.2024.155610\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><div>The high mortality rate of colorectal cancer (CRC) highlights the need for new treatment strategies; however, the venous invasion mechanisms in tumor endothelial cells within CRC remain unexplored. Therefore, we investigated the clinicopathological features of SRY-box transcription factor 17 (SOX17) in CRC. Immunohistochemical staining was performed on 55 CRC tissue specimens using a SOX17-specific antibody, followed by Kaplan–Meier and Cox proportional hazards regression analyses. SOX17 immunoreactivity was detected in the endothelial cells of tumor-penetrating vessels in 35/55 CRC samples. Kaplan–Meier analysis indicated that patients with SOX17 immunoreactivity had favorable overall and progression-free survival (log-rank test, <em>P</em> = 0.03 and 0.02, respectively). Notably, tumor endothelial SOX17 immunoreactivity was associated with a favorable prognosis in patients with stage III or IV disease (OS, <em>P</em> = 0.0089; PFS, <em>P</em> = 0.0065). Cox proportional hazard regression analysis indicated that SOX17 immunoreactivity is an independent factor for predicting favorable overall and progression-free survival in CRC (<em>P</em> = 0.02 and 0.01, respectively). The present findings suggest that SOX17 expression in tumor endothelial cells is a potential indicator of favorable prognosis in patients with CRC.</div></div>\",\"PeriodicalId\":19916,\"journal\":{\"name\":\"Pathology, research and practice\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":2.9000,\"publicationDate\":\"2024-09-25\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Pathology, research and practice\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0344033824005211\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"PATHOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pathology, research and practice","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0344033824005211","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PATHOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

结直肠癌（CRC）的高死亡率凸显了对新治疗策略的需求；然而，CRC 中肿瘤内皮细胞的静脉侵袭机制仍未得到探索。因此，我们研究了 SRY-box 转录因子 17（SOX17）在 CRC 中的临床病理特征。我们使用 SOX17 特异性抗体对 55 例 CRC 组织标本进行了免疫组化染色，然后进行了 Kaplan-Meier 和 Cox 比例危险度回归分析。在 35/55 例 CRC 样本中，肿瘤穿透血管的内皮细胞中检测到了 SOX17 免疫反应。Kaplan-Meier分析表明，具有SOX17免疫反应的患者总生存期和无进展生存期较好（log-rank检验，P=0.03和0.02）。值得注意的是，肿瘤内皮 SOX17 免疫反应与 III 期或 IV 期患者的良好预后相关（OS，P = 0.0089；PFS，P = 0.0065）。Cox比例危险回归分析表明，SOX17免疫反应性是预测CRC总生存期和无进展生存期的独立因素（P = 0.02和0.01）。本研究结果表明，肿瘤内皮细胞中SOX17的表达是预示CRC患者良好预后的潜在指标。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

SOX17 expression in tumor endothelial cells in colorectal cancer and its association with favorable outcomes in patients

The high mortality rate of colorectal cancer (CRC) highlights the need for new treatment strategies; however, the venous invasion mechanisms in tumor endothelial cells within CRC remain unexplored. Therefore, we investigated the clinicopathological features of SRY-box transcription factor 17 (SOX17) in CRC. Immunohistochemical staining was performed on 55 CRC tissue specimens using a SOX17-specific antibody, followed by Kaplan–Meier and Cox proportional hazards regression analyses. SOX17 immunoreactivity was detected in the endothelial cells of tumor-penetrating vessels in 35/55 CRC samples. Kaplan–Meier analysis indicated that patients with SOX17 immunoreactivity had favorable overall and progression-free survival (log-rank test, P = 0.03 and 0.02, respectively). Notably, tumor endothelial SOX17 immunoreactivity was associated with a favorable prognosis in patients with stage III or IV disease (OS, P = 0.0089; PFS, P = 0.0065). Cox proportional hazard regression analysis indicated that SOX17 immunoreactivity is an independent factor for predicting favorable overall and progression-free survival in CRC (P = 0.02 and 0.01, respectively). The present findings suggest that SOX17 expression in tumor endothelial cells is a potential indicator of favorable prognosis in patients with CRC.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Pathology, research and practice 医学-病理学

CiteScore

5.00

自引率

3.60%

发文量

405

审稿时长

24 days

期刊介绍： Pathology, Research and Practice provides accessible coverage of the most recent developments across the entire field of pathology: Reviews focus on recent progress in pathology, while Comments look at interesting current problems and at hypotheses for future developments in pathology. Original Papers present novel findings on all aspects of general, anatomic and molecular pathology. Rapid Communications inform readers on preliminary findings that may be relevant for further studies and need to be communicated quickly. Teaching Cases look at new aspects or special diagnostic problems of diseases and at case reports relevant for the pathologist''s practice.